Regeneron Pharmaceuticals (REGN) Leases (2016 - 2024)
Historic Leases for Regeneron Pharmaceuticals (REGN) over the last 12 years, with Q4 2025 value amounting to $576.7 million.
- Regeneron Pharmaceuticals' Leases fell 245.26% to $576.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $576.7 million, marking a year-over-year decrease of 245.26%. This contributed to the annual value of $576.7 million for FY2025, which is 245.26% down from last year.
- Latest data reveals that Regeneron Pharmaceuticals reported Leases of $576.7 million as of Q4 2025, which was down 245.26% from $591.2 million recorded in Q4 2024.
- Regeneron Pharmaceuticals' Leases' 5-year high stood at $631.3 million during Q4 2021, with a 5-year trough of $576.7 million in Q4 2025.
- Its 5-year average for Leases is $605.0 million, with a median of $605.7 million in 2023.
- Its Leases has fluctuated over the past 5 years, first plummeted by 174.24% in 2022, then tumbled by 245.26% in 2025.
- Regeneron Pharmaceuticals' Leases (Quarter) stood at $631.3 million in 2021, then fell by 1.74% to $620.3 million in 2022, then dropped by 2.35% to $605.7 million in 2023, then decreased by 2.39% to $591.2 million in 2024, then fell by 2.45% to $576.7 million in 2025.
- Its Leases was $576.7 million in Q4 2025, compared to $591.2 million in Q4 2024 and $605.7 million in Q4 2023.